{
  "id": "5e4b62946d0a277941000024",
  "type": "yesno",
  "question": "Is Dexmecamylamine effective for depression?",
  "ideal_answer": "No. Antidepressant effect of Dexmecamylamine (TC-5214) was not observed in clinical trials.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
    "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
    "http://www.ncbi.nlm.nih.gov/pubmed/25514064"
  ],
  "snippets": [
    {
      "text": "At treatment end, no significant differences were seen for change in MADRS total score with TC-5214 versus placebo. Furthermore, there were no significant differences in any of the secondary endpoints. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In these 2 flexibly-dosed studies, no specific therapeutic effects were observed for TC-5214 (1-4 mg BID) adjunct to antidepressant in the primary endpoint or any secondary endpoint; however, TC-5214 was generally well tolerated. In conclusion, no antidepressant effect of TC-5214 was observed in these studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No notable differences were observed between dexmecamylamine and placebo for any secondary end point.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TC-5214 ( dexmecamylamine ) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder ( MDD ) and is currently being evaluated by Targacept as a treatment for overactive bladder . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At treatment end, no significant differences were seen for change in MADRS total score with TC-5214 versus placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In these 2 flexibly-dosed studies, no specific therapeutic effects were observed for TC-5214 (1-4 mg BID) adjunct to antidepressant in the primary endpoint or any secondary endpoint; however, TC-5214 was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}